CompletedNot Applicable

Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops

United States20 participantsStarted 2023-12-13

Plain-language summary

This is a digital symptom tracking study of Formula C™, a full cannabis flower formulation, rich in cannabinoids and terpenes, that has been shown to improve symptoms in people with Long COVID. Participants 21 and older will take Formula C™ for 90 days. During that time, participants will answer weekly surveys to track symptoms and wellbeing.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Must be at least 21 years of age.
✓. Willing and able to read, understand, and sign the informed consent.
✓. Willing to comply with all study procedures.
✓. Must have device to access the internet to complete surveys online.
✓. A diagnosis of Long COVID from a health care provider.

Exclusion criteria

✕. Non-English speaking, as the surveys are developed in the English language.
✕. Known allergies to hemp seeds or hemp-derived products, medical cannabis, coconut oil.
✕. Pregnancy, or planning to become pregnant in the next 3 months

What they're measuring

Symptom and wellbeing change over 3 months

Timeframe: 90 days

Trial details

NCT IDNCT06163690

SponsorEndourage, LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-02

View on ClinicalTrials.gov More Long COVID trials